Loxo Oncol Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LOXO ONCOL, and when can generic versions of LOXO ONCOL drugs launch?
LOXO ONCOL has three approved drugs.
There are ten US patents protecting LOXO ONCOL drugs.
There are one hundred and ninety-three patent family members on LOXO ONCOL drugs in forty-seven countries and nine supplementary protection certificates in eight countries.
Drugs and US Patents for Loxo Oncol
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | 12,109,193 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 10,342,780 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | TABLET;ORAL | 218160-003 | Apr 10, 2024 | RX | Yes | No | 10,112,942 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | TABLET;ORAL | 218160-003 | Apr 10, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | 10,918,622 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Loxo Oncol Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Morocco | 54770 | ⤷ Sign Up |
United Kingdom | 201522245 | ⤷ Sign Up |
Ukraine | 122258 | ⤷ Sign Up |
China | 113636978 | ⤷ Sign Up |
Japan | 6945070 | ⤷ Sign Up |
Israel | 277576 | ⤷ Sign Up |
Japan | 7502365 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Loxo Oncol Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3390395 | 2024C/506 | Belgium | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIB; AUTHORISATION NUMBER AND DATE: EU/1/23/1738 20231031 |
3390395 | CR 2024 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031 |
3390395 | C03390395/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68733 30.11.2023 |
3390395 | 301262 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031 |
3390395 | 4/2024 | Austria | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 (MITTEILUNG) 20231031 |
3390395 | PA2024506 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIBAS; REGISTRATION NO/DATE: EU/1/23/1738 20231030 |
3390395 | 122024000010 | Germany | ⤷ Sign Up | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.